Accelerate to discover

Back to filter

Related topics

Introducing Cytek Cloud

Cytek Biosciences

Dec 1, 2022

Cytek Cloud is the new digital ecosystem that supports full spectrum flow cytometry research from panel design to data...

See More, Sort More with Cytek Full Spectrum Systems

Cytek Biosciences

Nov 28, 2022

Still wondering whether to join the shift to full spectrum cytometry?  Easily transfer assays from your Cytek Northern...

Demonstrate the value of RareCyte Orion system via web-based Minerva viewer

RareCyte

Nov 25, 2022

The HTA CRC Atlas X dataset contains images and other data being used for construction of an atlas of human colorectal...

ACCELA Educational webinar series: Unlocking Spatial Biology with RareCyte Orion Technology

RareCyte

Nov 16, 2022

Discover full slide, high-plex biomarker quantitation with the all-in-one spatial biology...

Dec 9, 2022

Practical aspects of an imaging study: live in vivo scanning

MOLECUBES

Nov 11, 2022

In this webinar, MOLECUBES will present a live in vivo demonstration, showing the entire workflow from animal...

All inside your incubator: xCELLigence eSight

Agilent technologies

Nov 3, 2022

Multiplex Live cell imaging and real-time biosensor measurement with xCELLigence eSight

Download the newest AVATAR data presented at CAR-TCR

Xcell Biosciences

Oct 21, 2022

Xcell Bio CSO, James Lim, presented new data showcasing improved potency of AVATAR-expanded CAR T cells and highlighted...

Dec 9, 2022

RareCyte Orion system advances Multi-modal digital pathology for colorectal cancer diagnosis

RareCyte

Oct 19, 2022

Precision medicine is critically dependent on better methods for diagnosing and staging disease and predicting drug...

Show all topics (10)

Human solid tumor cytomics: revealing novel melanoma and immune cell subsets

Jun 27, 2016

We know that cellular heterogeneity in the tumor microenvironment complicates the diagnosis and treatment of cancer. Tumors are complex, dynamic systems composed of diverse cell types in various functional states, including cancer cells and infiltrating immune cells. Resolving this cellular heterogeneity requires a single-cell approach, as analyses on bulk cell preparations mask the heterogeneity and complexity of the biological system and may lead researchers down the wrong path.
Cutting-edge single-cell analysis tools for exploring the genomic, transcriptomic and proteomic states of both tumor and related immune cells are enabling researchers to understand system heterogeneity, identify cells with previously unrecognized phenotypes and elucidate important therapeutic mechanisms.
Tumors are composed of diverse cell types, including cancer cells that can differentially evade therapy and immune cells that may aid or impede treatment. This webinar highlights high-content single-cell approaches developed by the Irish lab for systems immunology and cancer biology studies of human solid tumors, including melanoma and brain cancer. It also discusses technical and biological quality controls, computational analysis and the strengths of combining single-cell approaches, such as mass cytometry, phospho-flow, imaging, transcript profiling and sequencing. These cytomic approaches are especially powerful for dissecting cellular mechanisms of treatment response, monitoring key biomarkers and precise targeting of clinically relevant cell subsets.
Click to watch the video: https://www.fluidigm.com/media#075976ec-8d88-4516-b438-2909ad8f01b0

 

Application
Product news

Brand profile

Fluidigm

Fluidigm is a Molecular and Single Cell Biology company that creates microfluidic-based chips and instrumentation for Life-Science research.

Related products

A new standard for high-throughput real-time PCR, end-point PCR and digital PCR

show detail

The first automated solution for single-cell genomics, now capable of even more

show detail

Time-of-Flight Mass Cytometer for highly multi-parametric single cell data

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey